Want to join the conversation?
$BCR narrowed its 2016 net sales outlook as-reported basis to range of 7-8% from prior range of 6-8% and its sales, excluding impact of FX, forecast to 8-9% from prior range of 7-8.5%. $BCR raised its adjusted EPS projection to $10.10-10.20 from earlier estimate of $10.05-10.18. The revised EPS forecast represents 11-12% growth.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)